Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Should be noted - Epidiolex will be eligible for patent challenges on September 28, 2022.
Thanks for the post. I think this company will be just fine. I like the way they run their business. I happen to follow Pablo Zuanic, he's not pone to bluesky views. About as close as you can get for a analyst
Sure I am, there are many others you can mention as well. And, there are many times that number that failed. The biggest difference was institutional investment. Amazon wasn’t doing all that well until they switched their business model. Selling books on the internet is how they started.
Not the first inning, cannabis has been around for a long time and from what I hear the black market is getting by just fine.
My point was revenue by itself doesn’t tell the story. Show me P/E, show me PEG, and growth improvement of those two. And the other point is they paid 2.1 billion for a company, what’s that return looking like.
The SEC filings are going to come out shortly, that will also tell everybody how were doing.
Well, everything is still churning, very soft footings out there across the board. In regards to this one, Qt earning are coming out shortly, I would think the revenue will be ok, but last year and last quarter they were in the red. Yep, I’m aware of the reasons for it, but those reasons have now passed, bright new day and all that. In a simple point of view, you can’t run a, say Kool aid stand, sell it for a dollar a cup, and have it cost you 1.05 to make it. Regardless of how much you sell.
Projections for this one 30,40,50, someone posted a 89 the other day. I would love to see it. But that being said, somebody must have a far better vision then what I have, I’ll leave it at that, well almost. Extreme blue sky view points are hard to support, easy to say, but hard to support. IMO
That market, down turning on us and all. Son of a . . . Well, it seems like you think it’s turned the corner here. Good, I mean it was at 14 last week, 15 3mo’s ago and 22 5mo’s ago. Does that mean the bottoms in, in your view? Is this it, you calling it?
It's the other reg's you mentioned that will tell the tale.
Be that as it may 60 votes is still a tough number. We'll see.
Well thank you, I won't need the luck but I thank you for wishing it.
This time around it will be the earnings that will tell the story IMO
Someone is pushing in shares this morning. Let's see how it plays.
Well your right, IMO that FDA will consolidate the mom and pop stuff, but again IMO it will bring in some big players from Canada and big pharma.
I’m looking into this a little myself. Not sure how they came up with that 5 bil. A quick glance at the top 20 public cbd companies does seem to support your 1 bil unlikely statement. However, as I’m trying to learn, private companies and medical dispensaries also have an unknown, not reported amount to add in.
It will be interesting to see what the FDA regulations will EXACTLY do. I’m not on board yet that it will be happy days are here again. For me, I’ll wait and see.
Thanks for that finer detail. It’s appreciated. Thank you!
That’s some good input. Thank you!
Ok, got it. Thank you that!
Well first, you have a great weekend as well. When you have some time do you have any idea who makes that private brand? No rush, again when you have time, and thanks again.
For those who live in FL. I could use a little help. Regarding “Low-THC Cannabis (mgs CBD) ] I take that to mean less than .3 thc. Is that correct? If so what brand/brands of this do they sell. Is it a medical pharma brand or is it an off the shelve public brand, private brand? Is it paid for out of pocket or does it qualify for Medicare, insurance or something else?
I thank you for any help you can provide.
And again, no traction. 2 hr.’s to go. Dow is up 600 points. Cvsi has 22 trades- 4700 dollars—213 per trade.
a question then. today the markets up 600, but were down 2.3 percent.
RE: I don't know, did someone get a signal via the Bollinger Bands, RSI, or something ? Nope, it was the Senate and House news. I think my point has been made.
You want to break that down on your reasoning, and maybe go over your point that you made. I do understand the news yesterday, but that news is still in play today. Yet here we are in a up market.
FYI - FDA Impact On CBD Market: With Federal Regulation, CBD Sales Would Hit $11B By 2027, Without It? $4.5B Less
8:00 am ET July 14, 2022 (Benzinga) Print
Cannabis research and data firm Brightfield Group released its latest report Thursday on the U.S. CBD market confirming that the CBD industry is highly dependent on Food and Drug Administration (FDA) regulations.
The new report estimates that if federal regulation happens by 2024, CBD sales would reach $11 billion by 2027. Without it? The market would hit $6.5 billion by 2027, meaning that federal law changes would make for a $4.5 billion difference. The $11 billion under new federal laws, would be mostly led by ingestible product sales growth, including capsules and gummies.
Furthermore, per the report, the U.S. hemp-derived CBD market is projected to reach $5.0 billion in retail sales in 2022.
While struggling without federal regulations, some CBD companies are finding alternative ways to get established in the space. One is by creating a name in a wider wellness space, which they achieve by developing and advertising non-CBD products and teaming up with other non-CBD-related businesses. This way, they're in a position to create a new customer base.
Key Takeaways
The top 5 CBD companies are the same as last year, with Charlotte’s Web (OTCQX: CWBHF) and Your CBD Store (SUNMED) being the first two.
Businesses that have experienced notable gains in the first quarter of the year include High Tide (NASDAQ: HITI) with NuLeaf Naturals, FAB CBD and HeavenlyRx/Simply Better Brands (OTCQB: PKANF) with PureKana.
Charlotte’s Web continues to hold the biggest portion of online CBD sales, while Your CBD Store (SunMed) and CBD American Shaman dominate in brick-and-mortar sales.
Topicals are expected to reach 41.5% of grocery CBD sales, followed by tinctures with 19.1%.
FDA Impact On CBD Market: With Federal Regulation, CBD Sales Would Hit $11B By 2027, Without It? $4.5B Less
8:00 am ET July 14, 2022 (Benzinga) Print
Cannabis research and data firm Brightfield Group released its latest report Thursday on the U.S. CBD market confirming that the CBD industry is highly dependent on Food and Drug Administration (FDA) regulations.
The new report estimates that if federal regulation happens by 2024, CBD sales would reach $11 billion by 2027. Without it? The market would hit $6.5 billion by 2027, meaning that federal law changes would make for a $4.5 billion difference. The $11 billion under new federal laws, would be mostly led by ingestible product sales growth, including capsules and gummies.
Furthermore, per the report, the U.S. hemp-derived CBD market is projected to reach $5.0 billion in retail sales in 2022.
While struggling without federal regulations, some CBD companies are finding alternative ways to get established in the space. One is by creating a name in a wider wellness space, which they achieve by developing and advertising non-CBD products and teaming up with other non-CBD-related businesses. This way, they're in a position to create a new customer base.
Key Takeaways
The top 5 CBD companies are the same as last year, with Charlotte’s Web (OTCQX: CWBHF) and Your CBD Store (SUNMED) being the first two.
Businesses that have experienced notable gains in the first quarter of the year include High Tide (NASDAQ: HITI) with NuLeaf Naturals, FAB CBD and HeavenlyRx/Simply Better Brands (OTCQB: PKANF) with PureKana.
Charlotte’s Web continues to hold the biggest portion of online CBD sales, while Your CBD Store (SunMed) and CBD American Shaman dominate in brick-and-mortar sales.
Topicals are expected to reach 41.5% of grocery CBD sales, followed by tinctures with 19.1%.
Green Thumb Industries Extends Maturity Date Of Senior Debt Facility
7/14/22 9:39 AM ET (Benzinga)Print
Green Thumb Industries Inc. (OTCQX: GTBIF) (CSE:GTII) , a leading national cannabis consumer packaged goods company and owner of RISE dispensaries, has exercised its right to extend the maturity date of its senior non-brokered debt by one year, from April 30, 2024 to April 30, 2025.
The current senior secured notes, which have a total principal amount of approximately $250 million, bear interest at a rate of 7% per annum and is paid quarterly. The extended maturity date did not involve any amendments to the notes or any additional consideration to the existing lenders.
About Green Thumb Industries:
Green Thumb Industries Inc., a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM.
The company also owns and operates growing national retail cannabis stores called RISE. Headquartered in Chicago, Illinois, Green Thumb has 17 manufacturing facilities, 77 open retail locations and operations across 15 U.S. markets. Established in 2014, Green Thumb employs approximately 4,000 people and serves millions of patients and customers each year.
What It Takes To Become And Stay A Big Player In The Cannabis Industry, According To Trulieve's Kim Rivers
7/14/22 3:45 PM ET (Benzinga)Print
With cannabis reform becoming a global phenomenon, the question of its federal legalization in the U.S. has come down to when it will take place.
Kim Rivers, CEO of Trulieve Cannabis Corp. (OTCQX: TCNNF), who was a keynote speaker at the opening of the Benzinga Cannabis Capital Conference last fall, said that the southeast is the next new frontier of cannabis reform in the country.
Now with the Cannabis Capital Conference returning to Chicago this coming September 13-14, Rivers will again share her insights on running one of the companies whose stock is among analysts’ top picks quarter after quarter.
In nearly six years since founding Trulieve, the medical marijuana dispensing company has gone from a dozen employees to 8,000 with operations across 11 states.
Having strategy and "very identified targets with very specifically measurable results," as well as developing the business around key regions, "is what it takes to become and stay a big player in the cannabis industry,” said Rivers, who joined Trulieve at its inception.
Who Is Kim Rivers?
Prior to Trulieve, Rivers worked in private practice as a lawyer where she specialized in mergers, acquisitions, and securities for multi-million dollar companies. She also ran several successful businesses from real estate to finance.
Rivers, along with a significant number of the company’s executives including CFO Alex D'Amico, president Steve White and Christine Hersey, executive director of investor relations recently bought up a significant number of company shares.
Come and meet extraordinary cannabis visionaries and let’s network and learn together. Join us in September at the Benzinga Cannabis Capital Conference and stay at the historic Palmer House Hotel. Don't miss out on a chance to hear about future market forecasts and worldly advice on investing and finance from those embedded in the cannabis industry. Ready, set, go!
Verano Announces the Opening of MUV Sebring, the Company's 52nd Florida Location
Today 7:00 AM ET (GlobeNewswire)Print
EQNX::TICKER_START (CNSX:VRNO),(OTC US:VRNOF),(Other OTC:VRNOF),(CNSX:VRNO.CN), EQNX::TICKER_END Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) ("Verano" or the "Company"), a leading multi-state cannabis company, today announced the opening of MUV Sebring on Saturday, July 16, the Company's 52 Florida dispensary and 106 nationwide. MUV Sebring, located at 3900 US-27 North, is open Monday through Saturday from 9 a.m. to 7 p.m. and Sunday from 11 a.m. to 5 p.m., local time.
According to Florida's Office of Medical Marijuana Use, there are currently over 736,000 qualified medical cannabis patients in the state. Florida medical cannabis sales are projected to potentially reach $2.5 billion by 2026, as reported by MJBiz Factbook 2022.
"MUV Sebring marks our 52 retail location in Florida and our first in the Heartland region of the state," said John Tipton, President of Verano. "We are excited and ready to introduce the area's medical marijuana patient community to the MUV retail experience and our premium cannabis products."
As a demonstration of their commitment to provide a convenient and reliable experience for Florida patients, MUV dispensaries feature online menus for effortless browsing of their extensive, award-winning product selection, including the Company's signature Verano Reserve flower line. For additional convenience and accessibility, patients can choose to order ahead at muvfl.com or through the MUV mobile application available in the Google Play and Apple App stores for express in-store pickup.
MUV offers one-on-one virtual and in-store consultations at no cost to the patient. MUV's comprehensive product selection includes edibles, chocolates and lozenges, flower, pre-rolls, an array of vaporizer pens, concentrates, metered-dose inhalers, topicals and oral sprays; along with patented encapsulation formulations in its EnCaps(TM) capsules, tinctures, 72-hour transdermal patches and transdermal gels.
Well, as an example, the high one is most likely Andrew Partheniou, Stifel Nicolaus.
And if so his ranking is Ranked #7,506 out of 7,918 Analysts
Success rate 30.40%
Average return -13.50% Per rating
This just one example, there are many. It pays to review to get a proper frame of thought. IMO
fyi - The Food and Drug Administration announced it intends to award a contract to a company to “provide online data subscription and analytic services to help address knowledge gaps and contribute to the foundation of evidence needed on cannabidiol (CBD) and other cannabis products to help inform development of surveillance measures, guide prevention efforts, and target education/outreach initiatives.”
fyi The Food and Drug Administration announced it intends to award a contract to a company to “provide online data subscription and analytic services to help address knowledge gaps and contribute to the foundation of evidence needed on cannabidiol (CBD) and other cannabis products to help inform development of surveillance measures, guide prevention efforts, and target education/outreach initiatives.”
LOL. No, I don’t need to tell anybody they are wrong. Their companies they work for on the other hand may.
But to be fair, you didn’t mention if they are buy side or sell side. You didn’t mention if those were the projections they put out yesterday, or are they several months or longer ago. You didn't mention the last rerate.You didn’t mention if they are sponsored. And you didn’t mention what success rate their projections have been. A 10 percent rate is far different than a 90 percent rate.
You also mentioned revenue in another post. Yes, it’s very good revenue, but by itself is next to meaningless without at least mentioning that it costs more than a dollar for every dollar they take in. They are operating at a loss. So I guess with the record revenue they have record costs as well. Are there reasons, sure but failing to mention them is misleading. Kind of like a baseball team played today and scored 4 runs, did they win, lose, we don’t know do we.
So, 61 trades, 18 k- 295 per. wap- .0323. Better than yesterday
Hope all is well. Yes, great opportunity for smart people. But that boils down to selection and timing, or perhaps at times just dumb luck. Buying at the bottom, or just coming out of a recession is good times for those that timed a good selection.
Well, we know where we been, the future is not written, so sure, great things, good, fair, poor are all on the table. As far as management, genius? Who’s to say, at the end of the day they will absolutely be judged on what they did. Maybe their genius is just keeping afloat this long. Were going to see how it all plays.
You almost have to laugh. Now they say the bad times are going to be coming. So be it, I think were already there.
Remember way back to the start of the year, and this one was over .25 a share. Even in march we were at .17 a share until they out with year-end earnings.
The 1st qt conf. call with out questions. Yep, that was a hoot.
ASM which is when they went thru the motions of the vote they rigged, followed by the increase, raise they mentioned.
Milestones . . . . . . .
All I can say is fortunately they got those raises. Imagine how much worst it could have been.
Their gameplan has been to . . . . . . . .
But now if you listen to the talking heads on the economy, the bad times are coming!
So here we are, you know just 3 weeks ago or so we still have some action around a nickel. Now were having all we can do to hold 3 cents.
I think the next qt release will be reviewed, not only with a open mind, but also with no carrots, no blue sky, only what is. Show me the numbers.
First couple of hours. A little more activity today. 20 trades 3700 dollars 187 per trade.
RE: “All of this prediction stuff is a joke.” Well I'm sorry to hear that. I guess that means several hundred thousand quants and analysts and specialists are going to be out of work then. That’s a shame.
Ah yes, floundering oblivion. Nice to know your getting your jollies from it. Thanks for sharing.
Yes, they are RE: Validating the science and making moves forward. CW is leading the charge.
What do we have today. 37 trades – 6900 dollars – 186 per . We’ll call that light.
More avenues opening up. Nothing wrong with that. It's all good.
Trulieve Opening New Medical Marijuana Dispensary in Hollywood, FL
Today 7:43 AM ET (PR NewsWire)Print
New dispensary expands patient access to medical cannabis; grand opening specials available
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new medical dispensary in Hollywood, Florida. Located at 2908 Hollywood Blvd., the Hollywood dispensary opens at 9am on Tuesday, July 12, 2022, with ongoing regular hours of 9am - 9pm from Monday through Saturday and 10am - 8pm on Sunday.
https://mma.prnewswire.com/media/1857030/Hollywood_FL.jpg
Grand opening festivities throughout the day at the new dispensary will include numerous partner giveaways, music, food trucks, deals and specials, and all registered patients will receive a 25% discount. Trulieve also offers statewide home delivery, convenient online ordering and in-store pickup. As always, all first-time guests are eligible for a 50% new customer discount at any Florida-based location.
"Trulieve is excited to expand access to medical cannabis to more patients in Florida and build strong relationships in the Hollywood community," said Kim Rivers, CEO of Trulieve. "We are driven by our commitment to providing tailored, high-quality patient care in a safe and comfortable environment."
As the state's leading medical cannabis provider, Trulieve's retail employees are trained to provide personalized patient care and support individuals at every stage of their cannabis journeys. Trulieve dispensaries throughout Florida offer on-site consultations to help patients obtain appropriate medical products and dosages to ensure optimal cannabis experiences.
Trulieve patients across Florida can choose from the largest selection of THC and CBD products available in a variety of consumption methods, including smokable flower, concentrates, edibles, capsules, syringes, tinctures, topical creams, vaporizers, and more.
Designed to meet every patient's needs, our portfolio of in-house brands includes Alchemy, Co2lors, Cultivar Collection, Modern Flower, Momenta, Muse, Roll One and Sweet Talk. Patients also have access to beloved brands such as Bellamy Brothers, Bhang, Binske, Blue River, Black Tuna, DeLisioso, Love's Oven, Miami Mango, O.pen and Sunshine Cannabis, all available exclusively at Trulieve in Florida.
EXCLUSIVE: Ayr Wellness To Open Another Rec Cannabis Dispensary In Greater Boston Area
Today 6:53 AM ET (Benzinga)Print
Ayr Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF) is opening a new store in Watertown, its second retail location selling recreational marijuana in the Greater Boston area. The company will launch sales on Tuesday, July 12.
Located at 48 North Beacon Street, Watertown, Massachusetts, the store features a wide range of cannabis brands and products, including Ayr’s own Kynd premium flower, Entourage vapes, Secret Orchard vapes, Wicked edibles, Levia THC infused seltzer, and HAZE concentrates, to address experienced consumers as well as those newer to cannabis.
“The opening of AYR in Watertown is another amazing milestone for our team. We are thrilled to be adding a second adult-use dispensary in Greater Boston in another great location,” Jonathan Sandelman, founder, chairman and CEO of Ayr, said. “With our newly opened Back Bay dispensary hosting its Grand Opening Celebration on July 14th, this is an important week for Ayr in Greater Boston. We look forward to celebrating these milestones with the Watertown community, where we maintain our commitment to being a great neighbor and community partner.”